Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

46
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
46
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

298
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
298
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

79
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
79
Acute Pancreatitis II: Clinical Manifestations and Management01:30

Acute Pancreatitis II: Clinical Manifestations and Management

65
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
65
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

45
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
45

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Immune Architecture of Eosinophilic Esophagitis: Mechanisms, Therapeutic Targets, and Precision Management.

ImmunoTargets and therapy·2026
Same author

Recurrent Hepatic Encephalopathy After Abdominal Surgery in a Non-Cirrhotic Patient: A Case Report.

Reports (MDPI)·2026
Same author

Resolution of Hepatitis Delta Virus-Related Cryoglobulinemic Vasculitis With the Use of Bulevirtide.

ACG case reports journal·2026
Same author

Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis.

Clinical pharmacology and therapeutics·2026
Same author

Revisiting Abdominal Pain in IBS: From Pathophysiology to Targeted Management with Alverine Citrate/Simeticone.

Journal of clinical medicine·2026
Same author

The Therapeutic Pipeline for Eosinophilic Esophagitis: Current Landscape and Future Directions.

Pharmaceuticals (Basel, Switzerland)·2025

Related Experiment Video

Updated: May 8, 2025

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy
03:56

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy

Published on: September 13, 2022

2.3K

Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis.

Edoardo G Giannini1,2,3, Andrea Pasta1,2, Francesco Calabrese1,2

  • 1Gastroenterology Unit, Department of Internal Medicine, University of Genoa, Genoa, Italy.

Liver International : Official Journal of the International Association for the Study of the Liver
|December 25, 2024
PubMed
Summary
This summary is machine-generated.

For Primary Biliary Cholangitis (PBC) patients with incomplete response to ursodeoxycholic acid, elafibranor showed superior biochemical response compared to seladelpar. Seladelpar reduced pruritus, while obeticholic acid increased pruritus and serious adverse events.

Keywords:
bezafibrateelafibranorobeticholic acidresponseseladelpartreatmentursodeoxycholic acid

More Related Videos

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.4K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.3K

Related Experiment Videos

Last Updated: May 8, 2025

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy
03:56

A Two-Step Method for Percutaneous Transhepatic Choledochoscopic Lithotomy

Published on: September 13, 2022

2.3K
Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis
04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.4K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.3K

Area of Science:

  • Hepatology
  • Pharmacology
  • Clinical Trials

Background:

  • Primary Biliary Cholangitis (PBC) affects many patients who do not respond fully to ursodeoxycholic acid (UDCA).
  • Second-line therapies are crucial for preventing disease progression in non-responders.
  • A direct comparison of these second-line treatments was previously unavailable.

Conclusions:

  • Elafibranor offers a slight advantage in biochemical response over seladelpar.
  • Seladelpar uniquely provides a benefit in reducing pruritus incidence.
  • OCA showed comparable efficacy to other agents but with a higher risk profile for pruritus and SAEs, suggesting personalized treatment approaches for PBC.